WisdomTree BioRevolution Fund
$22.67−0.34 (−1.50%)
- 0.45%
- $5M
- +41.9%
- 3.35%
- 0M sh
- $23.45
- low $15.67high $24.74
The ETF.net WDNA Grade
C
Score 40 out of 100
- 11 of 17
Score 40 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Very small fund, grade capped at C.
The cap holds the Score at 40 or below, so B and A are out of reach.
- The pillars earned
- 47
- This cap took
- −7
- Published Score
- 40
Cost
The fund’s net expense ratio, ranked against its category.B56 out of 100Rank 7 of 17Mission
Whether the fund did what it promised, tested against its stated mandate.B66 out of 100Rank 7 of 9Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.D35 out of 100Rank 12 of 17Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.F0 out of 100Rank 17 of 17Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.A70 out of 100Rank 6 of 17Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.F20 out of 100Rank 16 of 17
Our read on WDNA
CMost biotech funds stop at drug developers. WDNA follows biology out of the clinic and into food, materials and industrial chemistry, tracking a WisdomTree index shaped with futurist Jamie Metzl.
The Fund seeks to track the WisdomTree BioRevolution Index before fees and expenses. It uses a passive representative-sampling approach to gain global equity exposure to companies expected to be significantly transformed by advances in genetics and biotechnology.
Why people hold it
- Wider map than a pipeline fund: the index sorts companies across human health, agriculture and food, materials/chemicals/energy, and biological machines and interfaces.wisdomtree.com
- The 0.45% expense ratio sits under the median for genomics and biotech thematics, which is unusual for a niche with this much research behind the index.
- Passive and global by design: roughly 100 listed names worldwide, sampled to track the WisdomTree BioRevolution Index rather than picked by a manager.wisdomtree.com
Worth knowing
- A small, thinly traded fund. Spreads can run wider than the category heavyweights, so the price you get may drift from the value of what you own.
- For plain biotech exposure, bigger peers cost less: IBBQ at 0.19% and XBI at 0.35%. You pay WDNA's fee for the broader multi-sector definition.
- The issuer flags the theme's own hazards: intense competition, fast product obsolescence, intellectual-property loss, and shifting government rules.wisdomtree.com
WDNA Holdings
- Stocks
- 87
- 42%
- MRNA
Sectors
- Health Care91.2%
- Materials5.4%
- Consumer Staples3.4%
Geography
- United States86.56%
- United Kingdom3.84%
- Switzerland2.60%
- Germany2.53%
- Denmark1.78%
- Netherlands1.51%
- Belgium0.65%
- Australia0.52%
WDNA Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Not enough history yet.
WDNA$14,192
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | WDNA |
|---|---|
| Year to date | +36.3% |
| 1 month | +3.9% |
| 3 months | +12.2% |
| 1 year | +41.9% |
| 3 years | +18.9% |
| 5 years | −0.2% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | WDNA |
|---|---|---|
| 2026 YTD | +36.3% | |
| 2025 | +22.7% | |
| 2024 | −14.1% | |
| 2023 | −2.1% | |
| 2022 | −26.3% | |
| 2021 | −5.3% |
WDNA in the news
WDNA Dividends
- 3.35%
- $0.77
- $0.77 per share
- Annual
Distribution history
WDNA Risk
- 25.4%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.64
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −56.8%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 1.26
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
WDNA Cost
0.45%
WDNA0.45%
- The middle half of Biotech & Genomics funds
- Median 0.47%
6 of the 17 Biotech & Genomics funds charge less.
Other funds in Biotech & Genomics
- CGNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETFExpense ratio 0.35%1 year return —
- CGNOMGlobal X - Genomics & Biotechnology ETFExpense ratio 0.50%1 year return +64.9%
- DHELXFranklin Genomic Advancements ETFExpense ratio 0.50%1 year return +31.8%
- DARKGARK Genomic Revolution ETFExpense ratio 0.75%1 year return +63.0%
- DBBCVirtus Biotech Clinical Trials ETFExpense ratio 0.65%1 year return +51.2%